Podcasts about adpkd

The FiltrateJoel TopfAC GomezSophia AmbrusoNayan AroraSpecial Guest Charles Edelstein, MD, PhD Professor, Medicine-Renal Med Diseases/HypertensionExtra-Special GuestMichelle Rheault, MD Professor of Pediatrics, University of MinnesotaEditing bySimon and Joel TopfThe Kidney Connection written and performed by by Tim YauShow NotesKDIGO ADPKD Guidelines:WebsiteGuideline PDFExecutive Summary PDFNephJC coverageConsortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP)Hy's Law (Wikipedia) has three components:ALT or AST by 3-fold or greater above the upper limit of normalAnd total serum bilirubin of greater than 2× the upper limit of normal, without findings of cholestasis (defined as serum alkaline phosphatase activity less than 2× the upper limit of normal)And no other reason can be found to explain the combination of increased aminotransferase and serum total bilirubin, such as viral hepatitis, alcohol abuse, ischemia, preexisting liver disease, or another drug capable of causing the observed injuryMeeting this definition yields a very high risk of fulminant kidney failure (76% in one series)Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database (PubMed) Two of 957 patients on tolvaptan met Hy's law criteria. None had fulminant kidney failure.Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial (PubMed) Patients had a baseline urine volume on tolvaptan of 6.9 L/24 h. Urine volume decreased to 5.1 L/24 h with hydrochlorothiazide and to 5.4 L/24 h on metformin.TEMPO 3:4 Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (NEJM)Reprise Trial Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease ( NEJM | NephJC )Unified ultrasonographic diagnostic criteria for polycystic kidney disease by Edelstein in JASN (PubMed)Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies (PubMed)Charles' draft choice Recommendation 4.1.1.1: We recommend initiating tolvaptan treatment in adults with ADPKD with an estimated glomerular filtration rate (eGFR) ‡25 ml/min per 1.73 m2 who are at risk for rapidly progressive disease (1B).Sophia's draft choice Recommendation 1.4.2.1: We recommend employing the Mayo Imaging Classi cation (MIC) to predict future decline in kidney function and the timing of kidney failure (1B).Progression to kidney failure in ADPKD: the PROPKD score underestimates the risk assessed by the Mayo imaging classification (Frontiers of Science)AC's draft choice Recommendation 9.2.1: We recommend targeting BP to ≤ 50th percentile for age, sex, and height or ≤ 110/70 mm Hg in adolescents in the setting of ADPKD and high BP (1D).HALT-PKD Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease (NEJM)Nayan's draft choice Recommendation 6.1.2: We recommend screening for ICA in people with ADPKD and a personal history of SAH or a positive family history of ICA, SAH, or unexplained sudden death in those eligible for treatment and who have a reasonable life expectancy (1D).Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease (CJASN)Surgical Clipping Versus Endovascular Coiling in the Management of Intracranial Aneurysms (PubMed) Clipping is associated with a higher rate of occlusion of the aneurysm and lower rates of residual and recurrent aneurysms, whereas coiling is associated with lower morbidity and mortality and a better postoperative course.Joel's editorial pick Recommendation 6.1.1: We recommend informing adults with ADPKD about the increased risk for intracranial aneurysms (ICAs) and subarachnoid hemorrhage (1C).Joel's first draft pick The bring out your dead pick:Recommendation 4.3.1: We recommend not using mammalian target of rapamycin (mTOR) inhibitors to slow kidney disease progression in people with ADPKD (1C).Recommendation 4.4.1: We suggest not using statins specfiically to slow kidney disease progression in people with ADPKD (2D).Recommendation 4.5.1: We recommend not using metformin specifically to slow the rate of disease progression in people with ADPKD who do not have diabetes (1B).Recommendation 4.6.1: We suggest that somatostatin analogues should not be prescribed for the sole purpose of decreasing eGFR decline in people with ADPKD (2B).Perfect match: mTOR inhibitors and tuberous sclerosis complex (Orphanet Journal of Rare Diseases)Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc. (BioSpace) This is press release about acquiring the mTor1 inhibitor.Joel's second draft pick Recommendation 4.2.1.1: We suggest adapting water intake, spread throughout the day, to achieve at least 2–3 liters of water intake per day in people with ADPKD and an eGFR ≥ 30 ml/min per 1.73 m2 without contraindications to excreting a solute load (2D).Nayan's bonus draft Practice Point 4.7.1: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) should not be used to slow eGFR decline in people with ADPKD.Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan (KIReports)SMART Trial of GLP-1ra in non-diabetics: Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial (PubMed)Tubular SecretionsNayan: Landman on Paramount Plus (IMDB)Sophia: PassNayan: steps in with The Pitt on HBO (Wikipedia)Charles: The White Lotus, Yellowstone 1923, Poirot (IMDB)AC: The PittMichael Crichton's Estate Sends The Pitt to the Courtroom (Vulture)Joel: I Must Betray you by Ruta Sepetys (Amazon)

On this ASN Kidney Translation Podcast, Dr. Matthew Sparks discusses key ADPKD studies: circadian clock disruption and cyst growth (JASN), depressive symptoms in adults with ADPKD (Kidney360), and biomarker-based kidney outcome prediction (CJASN).

Did you know that patient registries play a vital role in improving kidney disease treatment and outcomes? In this episode, we're diving into the KidneyCARE Study—a patient registry that uses real-world data to better care for people with kidney disease. We sat down with experts as they explained what a patient registry is and why people with kidney disease may want to join the KidneyCARE Study. In today's episode we heard from:    Kerry K. Willis PhD- Dr Willis is the Chief Scientific Officer of the National Kidney Foundation (NKF). Since joining NKF in 1998, her major focus has been on the analysis and application of clinical evidence to improve care and outcomes for people living with kidney disease. She oversees all NKF-sponsored research and professional education programs, including the Spring Clinical Meetings; population health programs that facilitate health system and practice engagement around CKD as a quality improvement target; the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines; KDOQI quality measurement initiative; and four peer-reviewed journals devoted to chronic kidney disease. She led the development of and currently manages the Kidney CARE (Community Access to Research Equity) Study, the first national CKD patient registry to combine patient-reported data with clinical data from electronic health records.     Rachel Claudin, BS, CCLS- Rachel Claudin is the Patient-Centered Research Director at the National Kidney Foundation (NKF). Her main work for the past three years has been focused on the advancement of the KidneyCARE Study. As a person living with Lupus Nephritis, she is excited for the patient-entered data collected by the Study to increase and improve kidney care research. Previous to the NKF, Rachel worked in hospital and hospice settings advocating for patients utilizing the shared decision-making model of healthcare. Cari Maxwell- Cari has lived with Polycystic Kidney Disease (ADPKD) since 1989, and her personal experience, along with the experiences of her father and two siblings, fuels her advocacy for advancements in PKD treatment. She participated in the Tolvaptan Reprise trial, which led to the first-ever FDA-approved treatment for ADPKD—a treatment she continues to benefit from today. As a member of the NKF Kidney Advocacy Committee, Cari is passionate about promoting patient education, early detection, and scientific progress through patient-centered clinical research. She is dedicated to ensuring that others have access to life-changing treatments and are empowered to advocate for their health through proactive care. Cari currently works in health care cost containment strategies, where she applies her expertise to enhance patient access and outcomes. Sandy Gilbert PhD- Sandy Gilbert is the Senior Director of Patient Outcomes Research at the National Kidney Foundation (NKF), where she manages the KidneyCARE (Community Access to Research Equity)™ Study. Since joining NKF in 2024, her focus has been on developing and overseeing this pioneering national kidney disease patient registry, the first to integrate patient-reported data with clinical data from electronic health records. The goal of the Registry is to generate critical insights into disease progression, treatment outcomes, and health disparities, in support of NKF's mission to improve kidney health and drive innovation in kidney research and healthcare. Sandy works closely with teams of researchers and health system partners to expand the study's reach and ensure that it reflects the needs of diverse patient populations, including those from underserved communities. Additional Resources: KidneyCare Study Information Contact Information: Call: 212.889.2210 ext.134 M-F 10am-4pm CT  Email: kidneycarestudy@kidney.org   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Polycystic kidney disease is the most common genetic kidney disease worldwide and is characterized by progressive development of kidney cysts. Author Nerra Dahl, MD, PhD, Mayo Clinic, discusses the pathophysiology, clinical presentation, diagnosis, prognosis, and treatment of ADPKD in adults, with JAMA Associate Editor David Simel, MD, MHS. Related Content: Autosomal Dominant Polycystic Kidney Disease

Missy Franklin was a 5x Olympic gold medalist and world record holder in the pool. Now outside of it, Franklin is having just as much success. She's a parent (3-year-old daughter, Kaitlyn, with her husband Hayes Johnson), a member of the media (hosts the podcast Unfiltered Waters with fellow Olympian Katie Hoff), and an ambassador for the USA Swimming Foundation. In this episode, we discuss the upcoming Olympic Trials with Franklin, who will be in Indianapolis with the USA Swimming Foundation and as media. Trials are the most stressful environment in swimming and if you are there for more than a couple days, you ride the emotional roller coaster of someone chasing the Olympic dream whether you want to or not. Missy does a great job putting this into words and expressing her excitement at how the team looks to be shaping up as Trials loom. Outside of swimming, Missy has also been heavily focused on working with Otsuka America Pharmaceutical, Inc. to raise awareness of autosomal dominant kidney disease (ADPKD). Readers can learn more on DiveIntoADPKD.com.

In this episode of the PKD Dietician podcast, host Diana Bruen talks with guest Emily Fraser about family planning with polycystic kidney disease (PKD). Emily shares her journey, including her decision to use IVF and preimplantation genetic testing (PTM) to conceive a child without ADPKD. We discuss the IVF process, and the emotional and ethical considerations often involved. The episode highlights the importance of genetic testing and the support available for those seeking to prevent passing PKD to their children. CONNECT WITH EMILY Website: https://www.emilyfraser.ca/ Instagram: https://www.instagram.com/thespooniementor/ Program: https://www.emilyfraser.ca/tsp CONNECT WITH pkDO PKD Outreach Foundation Website: https://www.pkdo.org/ Instagram: https://www.instagram.com/pkd_outreach/ Info on IVF + PGTM: https://www.pkdo.org/pkd-free-babies DISCLAIMER Content on The PKD Dietitian Podcast is for informational purposes, it isn't intended as medical advice. Please consult your Dietitian and/or healthcare provider for individual recommendations.

Recently the International Society of Nephrology (ISN) and the Polycystic Kidney Disease Foundation (PKDF) held a joint webinar to discuss and explore the significant impact of health disparities on the outcomes for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In the latest episode of the Global Kidney Care Podcast, Dr. Maria E. Diaz-Gonzalez de Ferris, Dr. Sambhavi Krishnamoorthy and patient advocate Funke Ojuri continue the conversation on Health disparities that are often driven by socioeconomic, racial, and geographic factors and how they play a crucial role in shaping the progression of ADPKD and its associated complications. 

In this episode, The PKD Dietitian geeks out a bit looking at the recently published results of the KETO-ADPKD trial. This is the very first randomized controlled trial (RCT) looking at PKD and ketogenic diet therapy, if there was any impact on the kidneys, or if it is even doable. Listen in for a look at: - what was being tested - how the study was set up - were there any significant results? - what did the ketogenic diet therapy look like - The PKD Dietitian's thoughts & questions CORRECTIONS All participants tested ketones at home using a breath meter. Only the Ketogenic Diet group had blood ketone levels tested, at their center visits. Participants in the Ketogenic Group received 10%, not 10 grams, of their fat from MCT. RESOURCES [FULL ARTICLE] Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD—a randomized controlled trial [EPISODE 33] What is Cystatin C and Should You Get it Tested? [EPISODE 20] How To Start Keto Safely for Polycystic Kidney Disease (PKD) LET'S GET SOCIAL INSTAGRAM: https://www.instagram.com/the.pkd.dietitian/ FACEBOOK: https://www.facebook.com/PKDdietitian WEBSITE: https://www.thepkddietitian.com/ DISCLAIMER: The PKD Dietitian Podcast is meant for educational purposes only. Information presented should not be used in place of advice from a medical professional.

Anne and Mike continue their conversation with David Rintell, Head of Patient Advocacy at BridgeBio, in part two of our autosomal dominant polycystic kidney disease (ADPKD) episode. Anne describes her recovery from the first kidney transplant along with the complications she attributes to her two native kidneys which were not removed during the initial surgery and issues with polycystic liver disease. In the 11 years following, Anne endured an operation to remove her native kidneys, followed by a double organ transplant, giving her both a new liver and kidney. Her first kidney transplant was generously gifted by a friend. However, Anne received her new liver and second kidney from a deceased donor, a distinctly different process. Anne and Mike express their gratitude for their good fortune while acknowledging the courage of the donor family to make the decision to give an extension on life to another human, when their loved one could no longer live.   Check out Anne and Mike's journey in their video, "The Search and the Gift" https://vimeo.com/33405248 . For more information about organ donation, visit http://donatelife.net/    To learn more about ADPKD, listen to Part 1 to hear Rachel Groth, Ph.D., Vice President of Research at BridgeBio X, explain why ADPKD develops, how it affects the kidneys, what complications may arise from ADPKD and why individuals with end-stage kidney disease receive dialysis or kidney transplants.

Title: “We named the new kidney - bean.” Anne is living with autosomal dominant polycystic kidney disease, (ADPKD)   Anne joins David Rintell, Head of Patient Advocacy at BridgeBio to talk about how autosomal dominant polycystic kidney disease (ADPKD) has impacted her and the lives of her family members. ADPKD weaves through the branches of Anne's family tree for generations. When Anne was only six years old, her father died at 46 of ADPKD related kidney failure, dialysis, and kidney transplantation. Two of Anne's five siblings have ADPKD. One had a successful kidney transplant, but another sibling died while on the waiting list for a new kidney. Anne wasn't surprised by her ADPKD diagnosis at age 25 and was hopeful for a better outcome than experienced by her father and her sibling since she received the diagnosis at a younger age. Progress was not reassuring to Mike, Anne's husband, when Anne's kidney function declined to less than 30%. Anne needed a kidney transplant, and soon. Motivated to find a donor and save her life, Mike created a robust campaign to locate a kidney for Anne. After many months of social posts, connections, conversations, prayers, and a documentary, a donor was discovered – a perfect match. The surgery was much quicker than the campaign. Anne left the hospital with her new kidney, appropriately named “bean,” just three days after her surgery. Rachel Groth, Ph.D., Vice President of Research at BridgeBio X, the company's dedicated lab space focused on cutting-edge early research discovery, provides an overview of ADPKD, a genetic condition that causes small fluid-filled sacs called cysts to develop in the kidneys. She explains why ADPKD develops, how it affects the kidneys, what complications may arise from ADPKD and why individuals with end-stage kidney disease receive dialysis or kidney transplants.

Patients may be the experts on their own conditions, but data that captures health-related quality of life is often underutilized in research. The PKD Foundation is working with IQVIA to create a registry of patients with autosomal dominant polycystic kidney disease, a rare kidney condition. The ADPKD registry focuses on patient-reported, health-related quality of life data. The organization believes the registry will not only provide new insights into the condition but help with the design of efficient clinical trials and accelerate the development of new treatments. We spoke to President and CEO of the PKD Foundation Susan Bushnell, Vice President of Research Programs at PKD Foundation Elise Hoover, and Senior Director of Global Strategic Planning for IQVIA's Integrated Health Practice David Voccola, about the new registry, how it is leveraging technology to enable patients to drive insights into their condition, and the challenges it needs to overcome.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.06.22.546046v1?rss=1 Authors: He, K., Sun, X., Chen, C., Luc, S., Hao, J., Zhang, Y., Huang, Y., Wang, H., Ling, K., Hu, J. Abstract: Tubulin polyglutamylation is a post-translational modification that occurs primarily along the axoneme of cilia. Defective axoneme polyglutamylation impairs cilia function and has been correlated with ciliopathies, including Joubert Syndrome (JBTS). However, the precise mechanisms regulating proper axoneme polyglutamylation remain vague. Here, we show that Cyclin-Dependent Kinase 6 (CDK6), but not its paralog CDK4, localizes to cilia base and suppresses axoneme polyglutamylation by phosphorylating RAB11-interacting protein FIP5 at site S641, a critical regulator of cilia import of glutamylases. S641 phosphorylation disrupts the ciliary recruitment of FIP5 by impairing its association with RAB11, thereby reducing the ciliary import of glutamylases. Interestingly, significant upregulation of CDK6 and defective axoneme polyglutamylation were observed in Autosomal dominant polycystic kidney disease (ADPKD) cells. Encouragingly, the FDA-approved CDK4/6 inhibitor Abemaciclib can effectively restore cilia function in JBTS and ADPKD cells with defective glutamylation and suppresses renal cystogenesis in an ex vivo ADPKD model. In summary, our study elucidates regulatory mechanisms governing axoneme polyglutamylation and suggests developing CDK6-specific inhibitors could be a promising therapeutic strategy to enhance cilia function in ciliopathy patients. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

CME credits: 0.50 Valid until: 31-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-2/13880/ This Expert Exchange webcast is designed to help improve clinicians' ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.=

CME credits: 0.50 Valid until: 24-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-1/13879/ This Expert Exchange webcast is designed to help improve clinicians' ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.=

CME credits: 0.50 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/prognostic-tools-in-the-management-of-adpkd/13877/ This Expert Exchange webcast is designed to help improve clinicians' ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD.

CJASN Editor-in-Chief Rajnish Mehrotra interviews 2022 CJASN Trainee of the Year winner Bart J. Kramers on his article, "Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD."

You can reduce your kidney stone risk with Polycystic Kidney Disease, and it's all about nutrition. This episode is all about picking the step that will serve you best and taking action! Here's a glance at the episode: Top 6 things you can start right now specifically for ADPKD and stone prevention Including my 3 core pillars of PKD Nutrition If you have had a stone → grab my freebie roadmap on what to do next Resources: Blog: Kidney Stones Risk & PKD, Are They Connected? Freebie: PKD & Kidney Stones - A Roadmap To Dietary Prevention Tracking: Cronometer Have a question for the PKD Dietitian or a topic you would like covered? >>> Contact The PKD Dietitian

CME credits: 0.50 Valid until: 17-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/imaging-in-the-diagnosis-and-management-of-adpkd/13876/ This Expert Exchange webcast is designed to help improve clinicians' understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.

Welcome to this episode of Physician's Weekly podcast. I am your host, Dr. Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician's Weekly. In this episode, we have two fascinating interviews. Physician's Weekly's Editorial Board Member Alex McDonald, MD, interviews Kavita Arora, MD, Division Director of General Obstetrics and Gynecology, University of North Carolina School of Medicine  (https://www.med.unc.edu/obgyn/directory/kavita-aurora-md-mbe-ms/) about how to flip the narrative that providing abortion service *is* healthcare. In this interview Dr. Arora is “Not sure that I would agree that the measures are well-intended; I think they are misogynistic and controlling of women. They invade patient-clinician privacy and the sacred relationship that happens in my exam room.”But first,  Physician's Weekly's senior editor Martta Kelly speaks with Dr. Osama Amro, Director of Swedish Polycystic Kidney Disease Center in Seattle, WA, about their multidisciplinary patient-centered approach to pain management strategies in the management of autosomal dominant polycystic disease (ADPKD). ADPKD is one of the most common genetic diseases in humans, affecting 1 in 400 individuals, and is the fourth most common cause of renal failure worldwide.  If one parent has ADPKD, the children have a 50% chance of inheriting the gene (though up to 10% of patients don't have a family history and have de novo mutations). Pain management is central to progressive ADPKD, as the cysts grow, the weight of the kidneys can affect other systems. Dr. Amro provides practical tips on both pharmacological and non-pharmacological approaches.Enjoy listening!

CME credits: 0.50 Valid until: 23-09-2023 Claim your CME credit at https://reachmd.com/programs/cme/management-of-adpkd/13878/ This Expert Exchange webcast is designed to help improve clinicians' ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Potter sequence 1:40, Renal agenesis 2:40, Renal cysts 4:01, Autosomal dominant polycystic kidney disease (ADPKD) 4:59, Autosomal recessive polycystic kidney disease (ARPKD) 6:40, MCKD and JNPH 7:58, Tuberous sclerosis 8:19, Von Hippel Lindau 8:57, Horseshoe kidney 9:53, Ureteropelvic junction obstructions 10:34,  Voiding cystourethrography (VCUG) 11:10, Vesicoureteral reflux 12:00, Posterior urethral valves 11:21, Hypospadias 14:15, Epispadias and bladder-exstrophy-epispadias-complex (BEEC) 15:10, Prune Belly Syndrome 15:58, Disorders of sexual development 16:36, Ambiguous genitalia 17:39, Embryology of sex differentiation 20:11, Anti-Mullerian hormone 20:52, Testosterone 21:19, Dihydrotestosterone 21:50, 5a-reductase deficiency 22:04, Androgen insensitivity syndrome 22:21, Aromatase deficiency 23:29, Congenital adrenal hyperplasia 24:25, 21-Hydroxylase deficiency 26:35, Other causes of CAH 30:36, Kallman syndrome 32:12, Semil-Lemil-Opitz syndrome 32:53, Practice questions 33:22

We are delighted to be joined this week by Dr Os Iyasere, Consultant Nephrologist in Leicester. Dr Iyasere will enlighten us on how to diagnose and manage patients with polycystic kidneys. Wonderful insight into autosomal dominant polycystic kidney disease. Enjoy listening. 

Polycystic kidney disease is an inherited disorder where clusters of cysts develop within the kidneys, causing the kidneys to enlarge and lose function over time. The cysts, which are noncancerous sacs containing fluid, vary in size, and they can grow to be large. This disorder can occur in children and adults.The two main types of polycystic kidney disease, caused by different genetic flaws, are: Autosomal dominant polycystic kidney disease (ADPKD). Signs and symptoms of ADPKD often develop between the ages of 30 and 40. In the past, this type was called adult polycystic kidney disease, but children can develop the disorder.Only one parent needs to have the disease for it to pass to the children. If one parent has ADPKD, each child has a 50% chance of getting the disease. This form accounts for most of the cases of polycystic kidney disease.  Autosomal recessive polycystic kidney disease (ARPKD). This type is far less common than is ADPKD. The signs and symptoms often appear shortly after birth. Sometimes, symptoms don't appear until later in childhood or during adolescence.Both parents must have abnormal genes to pass on this form of the disease. If both parents carry a gene for this disorder, each child has a 25% chance of getting the disease. Polycystic kidney disease also can cause cysts to develop in the liver and elsewhere in the body. The disease can cause serious complications, including high blood pressure and kidney failure.The disease varies greatly in its severity, and some complications from polycystic kidney disease are preventable. Lifestyle changes and treatments might help reduce damage to the kidneys from complications, but long-term interventions, including dialysis or kidney transplant, are sometimes needed.On this special Ask the Mayo Mom edition of the Mayo Clinic Q&A podcast, host Dr. Angela Mattke is joined by Dr. Christian Hanna, a pediatric nephrologist with Mayo Clinic Children's Center to discuss PKD in children.

This is an article summary of "Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease" by Fouad Chebib on behalf of coauthors.

Dr. Bart Kramers summarizes the results of his study "Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD," on behalf of his colleagues.

Dr. Kristen Nowak and Dr. Heather Farmer-Bailey summarize the findings from their study, "Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial," on behalf of their colleagues.

Pregnancy can be an exciting time for most people, but what does it look like if you are a kidney patient? What does pregnancy look like if they have kidney disease, are on dialysis, or have received a transplant? In this episode, we'll hear useful facts and tips from transplant nephrologist Dr. Mariana Markell, as well as personal stories from Cari Maxwell and Katie Reed, two mothers living with kidney disease.   In this episode, you'll hear from: Dr. Mariana Markell  Dr. Markell is a graduate of Yale University and New York Medical College and received her Residency and Fellowship training at Columbia-Presbyterian Hospital and UCLA Medical Center. At SUNY Downstate she has served as the Director of Inpatient Dialysis and created the first Transplant Nephrology Fellowship Program in New York City. She currently continues to care for general and transplant nephrology patients while serving at the Medical Director of Kidney Transplantation. Her research interests include the impact of social determinants of health and issues in women's health in the person with kidney disease. Katie Reed Katie Reed has autosomal dominant tubulointerstitial MUC1 kidney disease (ADTKD-MUC1) and is a recent recipient of a successful kidney transplant. Katie is a board member for the Rare Kidney Disease Foundation, which focuses on raising awareness of ADTKD, building up the ADTKD community, and advocating for patients and families. Katie and her husband reside in North Carolina and are parents to two young children. In their free time, you can find the Reeds out and about at local parks, watching a thrilling game of preschool-aged soccer, cheering for the Steelers, or taking over Disney World in matching family shirts. Professionally, Katie is a Managing Director with Afton Partners, a consultancy focused on funding policy, governance, and sustainability strategies for education and human services organizations. Cari Maxwell  Cari was diagnosed with Polycystic Kidney Disease (PKD) in 1989. Through healthy living and choices, she managed her disease on her own for many years following the example of her father, who experienced ESRD in the early 1980s. A registered organ donor provided a near-perfect matching kidney to him and that gift of life granted Cari and her family 31 additional years with him before he passed away in October of 2018. Advancements in treatment for PKD patients are very close to Cari's heart, not only for herself but also for her other two siblings and oldest child that are diagnosed with ADPKD and for the likelihood that her two younger children may also be one day. She was fortunate to be able to participate in the clinical trial for the first-ever FDA-approved treatment for PKD – a treatment she still benefits from today. Cari is a member of the National Kidney Foundation's Kidney Advocacy Committee, and she champions patient education, early detection, and scientific advancement through patient-oriented clinical research. She hopes that through her commitment to the awareness of chronic kidney diseases, others will take an active role in their health journey through early detection, healthy choices, and becoming a strong voice of advocacy for themselves and others. Cari is a wife and mother to three daughters and works full-time as the Director of Culture & Operations for a growing technology integration firm near Hershey, PA.   For more information on pregnancy and kidney disease, visit https://www.kidney.org/atoz/content/pregnancy.

CME credits: 0.50 Valid until: 30-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/ This Expert Exchange webcast aims to improve clinicians' awareness of emerging agents in the treatment of patients with ADPKD.

CME credits: 0.50 Valid until: 30-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/ This Expert Exchange webcast aims to improve clinicians' awareness of emerging agents in the treatment of patients with ADPKD.

CME credits: 0.50 Valid until: 15-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/ This Expert Exchange webcast aims to improve clinicians' ability to manage patients diagnosed with ADPKD.

CME credits: 0.50 Valid until: 15-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/ This Expert Exchange webcast aims to improve clinicians' ability to manage patients diagnosed with ADPKD.

CME credits: 0.50 Valid until: 04-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/ This Expert Exchange webcast aims to improve clinicians' ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

CME credits: 0.50 Valid until: 04-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/ This Expert Exchange webcast aims to improve clinicians' ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

CME credits: 0.50 Valid until: 04-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/ This Expert Exchange webcast aims to improve clinicians' ability to detect and diagnose ADPKD in at-risk patients.

CME credits: 0.50 Valid until: 04-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/ This Expert Exchange webcast aims to improve clinicians' ability to detect and diagnose ADPKD in at-risk patients.

The most common congenital cause of CKD, ADPKD is an important diagnosis to be aware of in adults. Come learn about its many complications and emerging therapies for the treatment of ADPKD. 

"Excited by the promise our research holds for PKD patients, we have been packaging a variety of PKD drugs into our nanoparticles, testing their ability to act as a courier service for renal drug delivery. We've been testing this process on drugs that show therapeutic benefits in animal models but are shadowed by off-target side effects. Because our nanoparticles can carry more than one drug — and even gene therapy — we can help develop and deploy a therapeutic combination that may soon offer patients more benefit than any single drug. Because the biology of ADPKD is not entirely understood, drug discovery has been slow. As we are seeing with the dramatic success of the COVID-19 vaccines, however, nanomedicine can catalyze research efforts. Nanoparticles offer a promising new way to deliver medicine, making it simultaneously less toxic and more effective." Eun Ji Chung is a biomedical engineer. She shares her story and discusses her KevinMD article, "Using nano 'couriers' to deliver PKD drugs to just the right address." (https://www.kevinmd.com/blog/2021/05/using-nano-couriers-to-deliver-pkd-drugs-to-just-the-right-address.html)

CME credits: 0.75 Valid until: 27-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/ This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

CME credits: 0.75 Valid until: 27-06-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/ This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Marc hat ein breites Kreuz und ist knapp über 2 Meter groß. Sein Hobby war Rugby und er hat sich bei der Feuerwehr engagiert. So lange, bis das nicht mehr ging. Seine Nieren sind in den letzten Jahren stark gewachsen und er hat immer wieder mit heftigen Schmerzen zu tun. Dazu kommen chronische Rückenprobleme. Er hat sich neue Hobbys gesucht und ist fest entschlossen, das Beste aus seiner Krankheit zu machen. Darüber, wie er es geschafft hat, sich von geliebten Hobbys zu verabschieden und wie er heute mit den Herausforderungen der Krankheit klar kommt spricht er in unserem Podcast.

Herausforderung Zystenleber Weil sie familiär vorbelastet ist hat Susanne geahnt, dass auch sie betroffen ist. 2013 hat sie die Krankheit dann so richtig aus der Bahn geworfen. Sie ist, wie sie selbst sagt „aus dem Leben geplumpst“. Seitdem gehören Schmerzen zu ihrem Alltag. Besonders die Zystenleber macht ihr zu schaffen. Monatelang hat sie erhöhte Entzündungswerte und die Ärzte sind ratlos, was sie dagegen tun können. Das einzige, was sie aktiv tun kann, ist, sich um ihr inneres Gleichgewicht zu kümmern, damit ihr Mut und Hoffnung nicht verloren gehen. So schafft es Susanne trotz aller Herausforderungen, positiv und optimistisch zu bleiben. Über ihre Krankheit und ihre Strategie, damit umzugehen spricht sie in unserem Podcast.

„Da kommt die Känguruhniere“ so wird Gerhard seit der Transplantation immer mal wieder begrüßt. Er hat eine Niere von seiner Schwester bekommen und die lebt in Australien. Deshalb die „Känguruhniere“. Die Zystennieren hat Gerhard von seiner Mutter geerbt. Als die Nierenfunktion langsam zurück ging kam die Frage nach einer Lebendspende auf. Spontan erklärte sich seine Schwester dazu bereit. Wie eine Lebendspende zwischen Australien und Bayern funktioniert und wie er heute mit seiner „Känguruhniere“ lebt, darüber erzählt Gerhard in unserem Podcast.

Mit Anfang 20 wird Stefanie als Notfall in die Klinik eingeliefert. Die Ärzte stellen fest, dass sie Zystennieren hat. Eine überraschende Diagnose für sie, denn in ihrer Familie war die Krankheit bisher unbekannt. Nach und nach beginnt sie sich mit der Krankheit und den möglichen Folgen auseinander zu setzen. Vorerst hat sie keine Einschränkungen, sie engagiert sich im Beruf und wird Mutter eines Sohnes. Fast 20 Jahre nach der Diagnose macht sich die Krankheit langsam bemerkbar: Hoher Blutdruck und ein zunehmendes Nierenvolumen. In den letzten beiden Jahren sind ihre Blutwerte deutlich schlechter geworden. Anfang 2021 liegt die Filtrationsrate der Nieren nur noch bei 15. Sie bereitet sich darauf vor, Dialysepatientin zu werden und hofft, dass sie ihr Leben so gut es geht weiterleben kann. Für sich selbst und ihren inzwischen achtjährigen Sohn.

Petra wusste, dass sie Zystennieren hatte. Daß die Krankheit auch andere Auswirkungen haben könnte, zum Beispiel Aneurysmen, das hatte ihr kein Arzt gesagt. Auch als sie über starke Kopfschmerzen klagte, wurde sie nicht untersucht. Dann platzte ein Aneurysma in ihrem Kopf. Drei Wochen Koma folgten. Als Pflegefall wollte man sie aus der Klinik entlassen. Aber Petra wollte wieder zurück ins normale Leben. Es war ein harter und steiniger Weg zurück, aber sie hat es geschafft. Petra ist heute mit Anfang 50 im vorzeitigen Ruhestand. Sie ist schneller erschöpft und braucht mehr Ruhe. Und das gönnt sie sich auch. Sie arbeitet wieder stundenweise, singt in zwei Bands und freut sich darüber, dass sie mittlerweile Oma ist. Anderen Betroffenen macht sie Mut, die Hoffnung nicht aufzugeben und sich nicht von jeder Diagnose gleich entmutigen zu lassen.

Zystennieren liegen bei Isabell in der Familie, deshalb ist sie von der Diagnose nicht überrascht. Als sie gerade Mitte 20 ist diagnostizieren die Ärzte bei ihr eine sehr schnell wachsende Zystenleber. Von Anfang an scheint eine Transplantation der einzige Ausweg zu sein. Mit Anfang 30 trägt Isabell, die ansonsten eher zierlich ist eine fast 10 KG schwere Leber im Bauch. Sie wird für eine Transplantation gelistet. Anfang 2021 bekommt sie tatsächlich eine neue Leber. Sie ist erleichtert – im doppelten Sinn – und freut sich auf ein neues Leben. Sobald es geht, will sie anfangen, für einen Halbmarathon zu trainieren. Ein neues Leben durch eine neue Leber.

Rare diseases affect nearly 30 million Americans each year. One rare, progressive kidney disease, known as Autosomal Dominant Polycystic Kidney Disease (ADPKD), is the most common, rare, inherited kidney disorder you’ve likely never heard of. My guest is Nephrologist, Dr. Meyon Park, Director of UCSF Polycystic Kidney Disease Center of Excellence, she shares the signs, symptoms and impact that ADPKD has on the kidneys.

Rare diseases affect nearly 30 million Americans each year. One rare, progressive kidney disease, known as Autosomal Dominant Polycystic Kidney Disease (ADPKD), is the most common, rare, inherited kidney disorder you’ve likely never heard of. My guest is Nephrologist, Dr. Meyon Park, Director of UCSF Polycystic Kidney Disease Center of Excellence, she shares the signs, symptoms and impact that ADPKD has on the kidneys.

Dr. Matthew B. Lanktree summarizes findings from his study "Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD," on behalf of his colleagues.

Gary takes on the real issues that the mainstream media is afraid to tackle. Tune in to find out the latest about health news, healing, politics, and the economy. George Orwell and 1984: How Freedom Dies Orwell's final warning - Picture of the future The Efficacy of Olive Leaf Extract on Healing Herpes Simplex Virus: A Randomized Double-blind Study Lorestan University of Medical Sciences (Iran), January 29, 2021   Herpes simplex virus (HSV), as a common infection in healthy individuals, is treated symptomatically, but drug resistance and the side effects of drugs have drawn the attention of researchers to complementary medicine. Olive Leaf Extract (OLE) has antiviral effects that may treat HSV. The current study aimed to compare the clinical effects of OLE and Acyclovir on HSV-1. Methods This randomized double-blind clinical trial was conducted on 66 patients who had already been diagnosed with HSV-1. The participants were randomized into two groups, receiving 2% OLE cream or 5% acyclovir cream five times a day for six days. The symptoms were evaluated before, and three and six days after the interventions. Data were analyzed using the SPSS software through the Kolmogorov-Smirnov test, chi-squared, t-test, and repeated measures ANOVA. Results The results showed clinical symptoms decreased in both groups during the study and both medications were effective in the treatment of HSV-1. However, the OLE group experienced less bleeding (P=0.038), itching (P=0.002), and pain (P=0.001) on the third day as well as less irritation (P=0.012), itching (P=0.003) and color change (P=0.001) on the sixth day compared to the acyclovir group. The treatment course for participants in the OLE group was shorter than in the acyclovir group (P = 0.001). Conclusion The evidence from these trials suggests the OLE cream is superior in the healing of episodes of HSV-1 over the acyclovir cream. Future studies are recommended to investigate if OLE could be an adjunct to acyclovir treatment.   How vitamins, steroids and potential antivirals might affect SARS-CoV-2 Study indicates that some vitamins, steroids and antivirals could bind to the Spike protein, and may inhibit virus infectivity, whereas high cholesterol may enable the virus University of Bristol (UK), January 29, 2021   Evidence is emerging that vitamin D - and possibly vitamins K and A - might help combat COVID-19. A new study from the University of Bristol published in the journal of the German Chemical Society Angewandte Chemie has shown how they - and other antiviral drugs - might work. The research indicates that these dietary supplements and compounds could bind to the viral spike protein and so might reduce SARS-CoV-2 infectivity. In contrast, cholesterol may increase infectivity, which could explain why having high cholesterol is considered a risk factor for serious disease. Recently, Bristol researchers showed that linoleic acid binds to a specific site in the viral spike protein, and that by doing so, it locks the spike into a closed, less infective form. Now, a research team has used computational methods to search for other compounds that might have the same effect, as potential treatments. They hope to prevent human cells becoming infected by preventing the viral spike protein from opening enough to interact with a human protein (ACE2). New anti-viral drugs can take years to design, develop and test, so the researchers looked through a library of approved drugs and vitamins to identify those which might bind to this recently discovered 'druggable pocket' inside the SARS-CoV-2 spike protein.  The team first studied the effects of linoleic acid on the spike, using computational simulations to show that it stabilizes the closed form. Further simulations showed that dexamethasone - which is an effective treatment for COVID-19 - might also bind to this site and help reduce viral infectivity in addition to its effects on the human immune system.  The team then conducted simulations to see which other compounds bind to the fatty acid site. This identified some drugs that have been found by experiments to be active against the virus, suggesting that this may be one mechanism by which they prevent viral replication such as, by locking the spike structure in the same way as linoleic acid. The findings suggested several drug candidates among available pharmaceuticals and dietary components, including some that have been found to slow SARS-CoV-2 reproduction in the laboratory. These have the potential to bind to the SARS-CoV-2 spike protein and may help to prevent cell entry.  The simulations also predicted that the fat-soluble vitamins D, K and A bind to the spike in the same way making the spike less able to infect cells.  Dr Deborah Shoemark, Senior Research Associate (Biomolecular Modelling) in the School of Biochemistry, who modelled the spike, explained: "Our findings help explain how some vitamins may play a more direct role in combatting COVID than their conventional support of the human immune system.  "Obesity is a major risk factor for severe COVID. Vitamin D is fat soluble and tends to accumulate in fatty tissue. This can lower the amount of vitamin D available to obese individuals. Countries in which some of these vitamin deficiencies are more common have also suffered badly during the course of the pandemic. Our research suggests that some essential vitamins and fatty acids including linoleic acid may contribute to impeding the spike/ACE2 interaction. Deficiency in any one of them may make it easier for the virus to infect." Pre-existing high cholesterol levels have been associated with increased risk for severe COVID-19. Reports that the SARS-CoV-2 spike protein binds cholesterol led the team to investigate whether it could bind at the fatty acid binding site. Their simulations indicate that it could bind, but that it may have a destabilising effect on the spike's locked conformation, and favour the open, more infective conformation. Dr Shoemark continued: "We know that the use of cholesterol lowering statins reduces the risk of developing severe COVID and shortens recovery time in less severe cases. Whether cholesterol de-stabilises the "benign", closed conformation or not, our results suggest that by directly interacting with the spike, the virus could sequester cholesterol to achieve the local concentrations required to facilitate cell entry and this may also account for the observed loss of circulating cholesterol post infection." Professor Adrian Mulholland, of Bristol's School of Chemistry, added: "Our simulations show how some molecules binding at the linoleic acid site affect the spike's dynamics and lock it closed. They also show that drugs and vitamins active against the virus may work in the same way. Targeting this site may be a route to new anti-viral drugs. A next step would be to look at effects of dietary supplements and test viral replication in cells." Alison Derbenwick Miller, Vice President, Oracle for Research, said: "It's incredibly exciting that researchers are gaining new insights into how SARS-CoV-2 interacts with human cells, which ultimately will lead to new ways to fight COVID-19. We are delighted that Oracle's high-performance cloud infrastructure is helping to advance this kind of world-changing research. Growing a globally-connected community of cloud-powered researchers is exactly what Oracle for Research is designed to do."     Researchers find melatonin is effective against polycystic kidney disease Concordia University (Canada), January 26, 2021 A hormone commonly associated with sleep-wake regulation has been found to reduce cysts in fruit flies, according to Concordia researchers. It's a finding that may affect the way we treat some kidney diseases and reduce the need for kidney transplants. In a new paper published in the journal Molecules, alum Cassandra Millet-Boureima(MSc 19) and Chiara Gamberi, affiliate assistant professor of biology, write that melatonin was found to reduce cysts in the renal tubules of fruit flies. These tubules are also found in more complex mammals, including humans, where they are called nephrons. This study, which builds on previous studies by Millet-Boureima and Gamberi, was co-authored by Roman Rozencwaig and Felix Polyak of BH Bioscience in Montreal. The researchers hope that their findings can be applied to treating people suffering from autosomal dominant polycystic kidney disease. ADPKD is a genetic chronic and progressive disease characterized by the growth of dozens of cysts in the nephrons. It is incurable and affects approximately 12.5 million worldwide. Similarities big and small Because nephrons in vertebrates are embedded in other tissue, the researchers experimented on Drosophila -- the common fruit fly. "Drosophila conserves many of the renal pathway components found in vertebrates and have anatomically isolated renal tubes," Gamberi explains. "With microdissection, we can isolate the tubules and conduct biochemical and molecular analysis." The researchers bred fruit flies bearing the Bicaudal C gene mutation. It is known to cause kidney cysts in all manner of living beings, from flies to frogs to mice to humans. Over 18 days, Millet-Boureima administered melatonin to 50 Drosophila and ethanol to a control group. She then dissected the flies and scored their cysts, a process yielding a cystic index. She found that the melatonin-treated flies had much fewer and smaller cysts than the control. Because Millet-Boureima was skilled at dissecting the insects and evaluating the recovered renal tubules, she was able to avoid bias in the count. She was also able to distinguish three separate sections of the Drosophila tubule, each with its own unique function, and assign the cysts to a particular section. After testing several compounds on the same family of cells, she observed different activities along the length of the tubule. The researchers realized that they could potentially develop targeted treatment depending on the location of the cysts in a patient's nephrons. "Biologically speaking, this has a lot of potential that we will obviously develop," Gamberi says. Helping without harming Though Gamberi says melatonin has not been previously used to treat PKD, she does think it holds some promise. PKD is a chronic disease, so treatment cannot include any toxic components. This rules out chemotherapy and tumour-killing antineoplastics used in oncology, for instance. However, melatonin is entirely non-toxic and shares certain properties with antineoplastics and anti-inflammatory agents. "We know from oncology that melatonin has two effects when it is administered with chemotherapy," Gamberi explains. "First, it acts as a drug adjuvant to the chemotherapy, making it work more effectively against cancer cells. Second, it appears to protect healthy cells from the toxicity of the chemotherapy. Basically, melatonin increases the specificity of the chemotherapy. We hope that it can have a similar positive effect when used with an anti-ADPKD drug like tolvaptan, which can damage the liver." The researchers are keen to share their findings as quickly as possible. "I hope there will be more research on the drugs we tested and that we get more results that will help the PKD community," Millet-Boureima says.     Gallic acid is a dual alpha/beta-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer  Saitama Medical Center (Japan), January 20, 2021   According to news reporting from Saitama, Japan, research stated, “Several plant-derived compounds have demonstrated efficacy in pre-clinical Alzheimer’s disease (AD) rodent models. Each of these compounds share a gallic acid (GA) moiety, and initial assays on this isolated molecule indicated that it might be responsible for the therapeutic benefits observed.”  Higher concentrations of GA are found in blueberry, blackberry, strawberry, plums, grapes, mango, cashew nut, hazelnut, walnut and tea.   The news correspondents obtained a quote from the research from Saitama Medical Center, “To test this hypothesis in a more physiologically relevant setting, we investigated the effect of GA in the mutant human amyloid beta-protein precursor/presenilin 1 (APP/PS1) transgenic AD mouse model. Beginning at 12 months, we orally administered GA (20 mg/kg) or vehicle once daily for 6 months to APP/PS1 mice that have accelerated Alzheimer-like pathology. At 18 months of age, GA therapy reversed impaired learning and memory as compared with vehicle, and did not alter behavior in nontransgenic littermates. GA-treated APP/PS1 mice had mitigated cerebral amyloidosis, including brain parenchymal and cerebral vascular beta-amyloid deposits, and decreased cerebral amyloid beta-proteins. Beneficial effects co-occurred with reduced amyloidogenic and elevated nonamyloidogenic APP processing. Furthermore, brain inflammation, gliosis, and oxidative stress were alleviated. We show that GA simultaneously elevates alpha- and reduces beta-secretase activity, inhibits neuroinflammation, and stabilizes brain oxidative stress in a pre-clinical mouse model of AD. We further demonstrate that GA increases abundance of a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10, Adam10) proprotein convertase furin and activates ADAM10, directly inhibits beta-site APP cleaving enzyme 1 (BACE1, Bace1) activity but does not alter Adam10 or Bace1 transcription. Thus, our data reveal novel post-translational mechanisms for GA.” According to the news reporters, the research concluded: “We suggest further examination of GA supplementation in humans will shed light on the exciting therapeutic potential of this molecule.” This research has been peer-reviewed.     Black cumin’s anti-inflammatory potential may have airways/asthma benefits: RCT   University College London, January 27, 2021   Supplements containing oil from black cumin (Nigella sativa) may improve asthma control and lung function, says a new study.   The seed and oil of Nigella sativa have been used extensively in traditional medicine in many Middle Eastern and Asian countries for the treatment of a range of conditions, including some immune and inflammatory disorders.   The new study, published in Phytotherapy Research , found that one gram per day of the oil for four weeks led to significant improvements in scores of asthma control and a “remarkable reduction of peripheral blood eosinophil count,” wrote the authors   “Eosinophil cell plays a major role in asthma inflammation, and blood eosinophil count is considered to be a vital biomarker in asthma trials. To our knowledge, this is the first [randomized, double-blind, placebo-controlled trial] that showed a significant reduction of blood eosinophilia by [Nigella sativa oil (NSO)] among asthmatic patients.”   Scientists from University College London (UK) and King Abdulaziz University (Saudi Arabia) recruited 80 asthmatics and randomly assigned them to one of two equal groups. The participants received either capsules containing 500 mg of NSO twice per day or placebo for four weeks.   Data from the 60 people who completed the study (10 dropouts in each group) indicated that the black cumin supplement was associated with significant improvements in mean score on the Asthma Control Test, compared to placebo.   Black cumin oil products are commercially available through brands such as Life Extension. Structure-function claims made on the products include: “Modulates key regulators of inflammation” In addition, the black cumin group also experienced a significant decrease in blood eosinophils: −50 versus 15 cells/microliter.   A non-statistically significant improvement in lung function, measured as forced expiratory volume in 1 second, was also associated with the black cumin supplements.   “The NSO supplementation appeared to be effective in enhancing the control of asthma symptoms with a trend in pulmonary function improvement,” wrote the researchers. “These findings may provide an evidence for the potential benefits of NSO supplementation in the clinical management of asthma. “Future studies should follow patients for a longer period and use additional outcomes to validate the benefits of NSO in asthma.”   LSD may offer viable treatment for certain mental disorders McGill University (Quebec), January 26, 2021 Researchers from McGill University have discovered, for the first time, one of the possible mechanisms that contributes to the ability of lysergic acid diethylamide (LSD) to increase social interaction. The findings, which could help unlock potential therapeutic applications in treating certain psychiatric diseases, including anxiety and alcohol use disorders, are published in the journal PNAS. Psychedelic drugs, including LSD, were popular in the 1970s and have been gaining popularity over the past decade, with reports of young professionals claiming to regularly take small non-hallucinogenic micro-doses of LSD to boost their productivity and creativity and to increase their empathy. The mechanism of action of LSD on the brain, however, has remained a mystery. Studies in mice provide clues To conduct their study, the researchers administered a low dose of LSD to mice over a period of seven days, resulting in an observable increase in the sociability of the mice. "This increased sociability occurs because the LSD activates the serotonin 5-HT2A receptors and the AMPA receptors -- which is a glutamate receptor, the main brain excitatory neurotransmitters -- in the prefrontal cortex and also activates a cellular protein called mTORC 1," explains Danilo De Gregorio, PharmD, PhD, who is a postdoctoral fellow in the Neurobiological Psychiatry Unit at McGill and the study's first author. "These three factors, taken together, promote social interaction in mice, which is the equivalent of empathy and social behaviour in humans."  The researchers note that the main outcome of their study is the ability to describe, at least in rodents, the underlying mechanism for the behavioural effect that results in LSD increasing feelings of empathy, including a greater connection to the world and sense of being part of a large community. "The fact that LSD binds the 5-HT2A receptor was previously known. The novelty of this research is to have identified that the prosocial effects of LSD activate the 5-HT2 receptors, which in-turn activate the excitatory synapses of the AMPA receptor as well as the protein complex mTORC1, which has been demonstrated to be dysregulated in diseases with social deficits such as autism spectrum disorder," as specified by Prof. Nahum Sonenberg, Professor at the Department of Biochemistry of McGill University, world renowned expert in the molecular biology of diseases and co-lead author of the study. Using the cutting-edge technique of optogenetics, a technique where genes for light-sensitive proteins are introduced into specific types of brain cells in order to monitor and control their activity precisely using light signals, the researchers observed that when the excitatory transmission in the prefrontal cortex is de-activated, the prosocial effect of LSD was nullified, highlighting the importance of this brain region on the modulation of the behavioural effects of LSD. Moving forward to apply the findings to humans Having found that LSD increases social interaction in mice, the researchers are hoping to continue their work and to test the ability of LSD to treat mutant mice displaying the behavioural deficits similar to those seen in human pathologies including autism spectrum disorders and social anxiety disorders. The hope is to eventually explore whether micro-doses of LSD or some novel derivates might have a similar effect in humans and whether it could also be a viable and safe therapeutic option.  "Social interaction is a fundamental characteristic of human behaviour," notes the co-lead author Dr. Gabriella Gobbi, Professor in the Department of Psychiatry at McGill and psychiatrist at the McGill University Health Centre. "These hallucinogenic compounds, which, at low doses, are able to increase sociability may help to better understand the pharmacology and neurobiology of social behavior and, ultimately, to develop and discover novel and safer drugs for mental disorders."   Polyphenol-rich virgin olive oil reduces insulin resistance and liver inflammation and improves mitochondrial dysfunction   University of Naples (Italy), January 28, 2021   Studies from University of Naples Federico II Describe New Findings in Insulin Resistance (Polyphenol-rich virgin olive oil reduces insulin resistance and liver inflammation and improves mitochondrial dysfunction in high-fat diet fed rats)   A new study on Endocrine System Diseases and Conditions - Insulin Resistance is now available. According to news reporting originating in Naples, Italy, research stated, "Virgin olive oil is an essential component of the Mediterranean diet. Its antioxidant and anti-inflammatory properties are mainly linked to phenolic contents."   The news reporters obtained a quote from the research from the University of Naples Federico II, "This study aims to evaluate the beneficial effects of a polyphenol-rich virgin olive oil (HPCOO) or olive oil without polyphenols (WPOO) in rats fed high-fat diet (HFD). Male Sprague-Dawley rats were divided into four groups based on the different types of diet: (I) standard diet (STD); (II) HFD; (III) HFD containing WPOO, and (IV) HFD containing HPCOO. HPCOO and WPOO induced a significant improvement of HFD-induced impaired glucose homeostasis (by hyperglycemia, altered oral glucose tolerance, and HOMA-IR) and inflammatory status modulating pro-and anti-inflammatory cytokines (TNF-a, IL-1, and IL-10) and adipokines. Moreover, HPCOO and less extensively WPOO, limited HFD-induced liver oxidative and nitrosative stress and increased hepatic fatty acid oxidation. To study mitochondrial performance, oxidative capacity and energy efficiency were also evaluated in isolated liver mitochondria. HPCOO, but not WPOO, reduced H O release and aconitase activity by decreasing degree of coupling, which plays a major role in the control of mitochondrial reactive oxygen species emission."   According to the news reporters, the research concluded: "HPCOO limits HFD-induced insulin resistance, inflammation, and hepatic oxidative stress, preventing nonalcoholic fatty liver disease progression."   For more information on this research see: Polyphenol-rich virgin olive oil reduces insulin resistance and liver inflammation and improves mitochondrial dysfunction in high-fat diet fed rats.   

Judith Heida provides a summary of her article, "Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression," on behalf of her colleagues.

Der PKD Netzwerker Die Diagnose war für ihn eine Überraschung, obwohl PKD in seiner Familie schon bekannt war. Die Krankheit war ein Tabuthema. Als er 27 ist, schickt ihn seine Mutter zum Arzt. Der konfrontiert Uwe mit der Diagnose. Er muss alleine damit klarkommen. Als die Krankheit ihm mehr und mehr zu schaffen macht, sucht er nach anderen Betroffenen, mit denen er sich austauschen kann. Der Verein PKD e.V. geht auf seine Initiative zurück. In den letzten 10 Jahren hat er den Verein maßgeblich geprägt und aufgebaut. Vor allem die Vernetzung mit Betroffenen und Fachleuten aus aller Welt liegt ihm am Herzen. Über seine Geschichte mit PKD spricht Uwe in unserem Podcast.

Join Anthony and Juliet as they dive into the worl of ADPKD, the most common single gene disorder. Tune in to learn the biology and history of a condition responsible for a large proportion of the people on dialysis.

„Bist du Schwanger“ wurde Andrea schon in der ersten Klasse von einem Mitschüler gefragt. „Nein, ich habe Zystennieren“ war ihre Antwort. ARPKD nennt sich die Version von Zystennieren, die schon bei Säuglingen auftritt. Der Verlauf der Krankheit ist sehr unterschiedlich. Viele Betroffene Kinder sterben früh, müssen an die Dialyse oder transplantiert werden. Andrea lebt seit 30 Jahren mit der Krankheit und ihre Nieren funktionieren noch. Im Podcast erzählt sie, wie sie ARPKD als Kind und Jugendliche erlebt hat, wie sie heute mit der Krankheit umgeht und was sie sich für ihre Zukunft erhofft.

Many of us may likely know someone living with Polycystic Kidney Disease (PKD) and not even realize it. In fact, a genetic, progressive form of PKD, known as auto-somal polycystic kidney disease, or ADPKD, is the most common inherited kidney disorder you’ve likely never heard of. Joining me today in honor of PKD Awareness Day, is Dr. Meyeon Park, a leading nephrologist with the University of California San Francisco.

Many of us may likely know someone living with Polycystic Kidney Disease (PKD) and not even realize it. In fact, a genetic, progressive form of PKD, known as auto-somal polycystic kidney disease, or ADPKD, is the most common inherited kidney disorder you’ve likely never heard of. Joining me today in honor of PKD Awareness Day, is Dr. Meyeon Park, a leading nephrologist with the University of California San Francisco.

Robert Bacallao, MD, is a Professor of Medicine and an Adjunct Professor of Anatomy, Cell Biology & Physiology at the Indiana University School of Medicine. Dr. Bacallao completed his training from the University of Illinois and completed his fellowship in Nephrology from UCLA. Dr. Bacallao is widely regarded for his research on polycystic kidney disease, and has published extensively on its pathogenesis. He is the founder of Apoptocys, a company which aims to bring novel therapy interventions to people with ADPKD. He is involved in medical student, resident, and fellow training as a faculty member at Indiana University. As a physician, hard work is par for the course. But as Dr. Bacallao reminds us, the hard work is what sets you up for success when the door of opportunity opens. Today, we learn what it means to prepare for greatness. We learn about the power of the helping hand: We don't often get to where we're going alone. We are also reminded that arrogance blocks communication between us and our patients, therefore it is key to set our ego aside. We also need to find ways to break out of our shell and learn outside of medicine. It will give us new ways to communicate with, and understand the patient in the room. Pearls of Wisdom: 1. Understand the power of the helping hand. Our careers are formed as a result of the blessings of many people in our life. 2. Hard work allows you to be prepared when the door opens. You have to be standing at the net with the racket. 3. Get out of your shell. We need to look outside of medicine in order to broaden our thinking. This is instrumental in understanding the lives of our patients.

Dr. Meyeon Park, MD, MAS, Director of UCSF Polycystic Kidney Disease Center of Excellence and a Nephrologist discusses polycystic kidney disease (PKD) and autosomal dominant polycystic kidney disease (ADPKD) a genetic disorder which can eventually lead to kidney failure. She also talks about how people living with this disease can manage their condition. Dr. Park is speaking on behalf of Otsuka America Pharmaceutical, Inc. #PKD #ADPKD

Dr. Marie Hogan and Dr. Tetyana Masyuk provide a summary of their study "Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement."

Dr. Marie Hogan and Dr. Tetyana Masyuk provide a summary of their study "Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement."

In this episode, Dr. Carlos Bejar leading nephrologist at The Kidney and Hypertension Group of South Florida and faculty member at the University of Miami Miller School of Medicine offers an elegant and pragmatic review of the diaagnosis , classsification and  clinical chracteristics of patients with Autosomal Dominant Polycystic Kidey Disease (ADPKD). Type 1 (rapidly progressive) and Type 2 (slowly progressive) are covered in detail. Dr Bejar also talks about comprehensive management strategies, indications for novel therapeutic agents and clinical outcomes . He also discusses emerging and promising therapies for these patients and  talks about kidney transplantation in ADPKD, and what the future holds for this common form of congenital kidney disease. Does drinking water in large amounts slow the disease? He gives us his answer on that, as well.

Major Depressive Disorder affects more than 350 million people worldwide1. The reported prevalence of depression in patients with Chronic Kidney Disease (CKD) ranges from 20-65%2. This webinar provides an overview of both MDD and CKD and discusses their overlap of symptomology. Featuring: • Chris Bojrab, MD, Psychiatrist Team Psychiatrist for the Indiana Pacers • Rima Kang, MD, Nephrologist Assistant Professor of Clinical Medicine, Division of Nephrology at the Ohio State University 1World Health Organization. Fact Sheet on Depression. (2012) http://www.who.int/mediacentre/factsheets/fs369/en/index.html 2Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202. Chris Bojrab, MD has served as President of Indiana Health Group since 2003. Dr. Bojrab is the team psychiatrist for the Indiana Pacers, and serves as the psychiatric consultant to the Indianapolis Colts and the Indianapolis Indians. He is active in organized medicine on a state and national level having served as President of the Young Physician Section of the Indiana State Medical Association as well as holding offices in the American Medical Association and the American Psychiatric Association. Dr. Bojrab graduated from Wabash College and then attended Indiana University School of Medicine where he received his M.D. He completed a four-year residency in psychiatry at the Indiana University Medical Center where he served as Chief Resident. Rima Kang, MD, is an Assistant Professor of Clinical Medicine, within the Division of Nephrology at The Ohio State University, in Columbus, Ohio. Upon joining faculty at Ohio State, Dr. Kang has become the lead nephrologist in cystic kidney disease care and was instrumental in developing a specialty clinic at Ohio State with an emphasis in ADPKD and CKD. Dr. Kang continues to advocate for improved patient care and is an active member in multiple associations and committees, including the National Kidney Foundation (NKF), the Internal Medicine Quality and Patient Safety Committee, and the Internal Medicine Diversity and Inclusion Committee. Dr. Kang received her medical degree from Northeast Ohio Medical University, and completed her residency in Internal Medicine at the University of Cincinnati Medical Center in Cincinnati, Ohio. Dr. Kang then went on to complete a distinguished fellowship in Nephrology at The Ohio State University Wexner Medical Center. Disclaimers Chris Bojrab and Rima Kang are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.

Optimizing Care of Patients With ADPKD in Primary Care: Expert Insights to Improve Patient Outcome

Optimizing Care of Patients With ADPKD in Primary Care: Expert Insights to Improve Patient Outcome

Optimizing Care of Patients With ADPKD in Primary Care: Expert Insights to Improve Patient Outcome

Dr. Neera K. Dahl, MD, PhD, a leading nephrologist at Yale School of Medicine who specializes in diagnosing and treating kidney ailments and genetic kidney disorders such as ADPKD, shares important information on ADPKD and living with the condition. She also helps educate patients on how accepting their diagnosis and learning to manage their symptoms can help them take charge of their life with ADPKD. Dr. Neera Dahl, here on behalf of Otsuka America Pharmaceutical, Inc.

As someone who has had kidney disease since age 2 back in 1968, Lori Hartwell has witnessed many exciting medical breakthroughs throughout her life. Today she speaks with Geoffrey Block, MD, vice president, nephrology, at Reata Pharmaceuticals, about some of those breakthroughs. Dr. Block is part of a team researching a new, regenerative medicine to improve kidney function in those with rare forms of kidney disease such as Alport Syndrome, autosomal dominant polycystic kidney disease (ADPKD), and focal segmental glomerulosclerosis (FSGS). Listen in to this show to hear the encouraging results of the team™s published clinical research.

See the full story with pictures at: https://www.otsuka.co.jp/en/company/global-topics/2019/20190502_vol109.html Otsuka received the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the NKF 2019 Spring Clinical Meetings in Boston during May. The Corporate Innovator Award was established to recognize companies that advance the field of nephrology by addressing an unmet medical need, or improving upon an existing practice, therapeutic or technology. Otsuka Pharmaceutical received this award in recognition for its work in bringing JYNARQUETM (tolvaptan) to market. Kevin Longino, the CEO of National Kidney Foundation who is also a kidney transplant recipient, noted, “The Corporate Innovator Award recognizes Otsuka’s significant contribution to improving the lives of people with ADPKD and we congratulate them on this achievement.” The award was accepted on behalf of Otsuka by Louis Allesandrine, Vice President, Oncology and Nephrology Sales and Marketing at Otsuka America Pharmaceutical, Inc. He commented during the award presentation, “It is an honor and a privilege to accept this award on the behalf of the many people who made this possible, including patients, families, researchers, nephrologists, and Otsuka.” In April 2018, JYNARQUETM was approved by the U.S. Food and Drug Administration as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Earlier, the drug was approved for use in the EU, Japan and several other countries.   The National Kidney Foundation is the largest, most comprehensive and longstanding organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease.

This summary by Dr. Gianluigi Zaza, on behalf of his colleagues, discusses, "Proteomic Analysis of Urinary Microvesicles and Exosomes in Medullary Sponge Kidney Disease and Autosomal Dominant Polycystic Kidney Disease".

This summary by Dr. Gianluigi Zaza, on behalf of his colleagues, discusses, "Proteomic Analysis of Urinary Microvesicles and Exosomes in Medullary Sponge Kidney Disease and Autosomal Dominant Polycystic Kidney Disease".

Optimizing Care of Patients With ADPKD in Primary Care: Expert Insights to Improve Patient Outcomes

This is a summary of "Vascular Dysfunction, Oxidation Stress, and Inflammation in ADPKD" by Kristen Nowak and Berenice Reed-Gitomer, on behalf of their colleagues.

This is a summary of "Vascular Dysfunction, Oxidation Stress, and Inflammation in ADPKD" by Kristen Nowak and Berenice Reed-Gitomer, on behalf of their colleagues.

See the full story with pictures at: https://www.otsuka.co.jp/en/company/global-topics/2018/20180605_vol104.html Bill Brazell was ecstatic on April 24 upon reading a decision he has long advocated for and awaited: U.S. regulatory approval of Otsuka’s tolvaptan for use in slowing the progression of ADPKD (autosomal dominant polycystic kidney disease) in patients at risk of rapid progression. ADPKD is a progressive, inherited condition in which cysts proliferate in the kidneys, often leading to kidney failure.   Having lost numerous relatives to ADPKD, and some years after being diagnosed himself, Bill realized that remaining quiet about his condition was of no help to anyone. And so he began to do everything in his power to advance awareness of ADPKD as well as the search for a first treatment and an eventual cure. Bill’s awareness-raising has included contacting legislators, appearing on national TV and even wearing a kidney costume in the park to raise research funds for the PKD Foundation, where Bill has volunteered as a board member for nine years. To support the advance toward an ADPKD treatment, Bill participated for over 12 years in the clinical trials for tolvaptan, which culminated in the U.S. regulatory approval on April 24. He notes, “Even the possibility of a treatment changed my life and during the trial I and the woman I love decided to marry. We now have three wonderful children, and I do worry about them, but the news of the tolvaptan approval for ADPKD provides me and my family with tremendous hope.”

See the full story with pictures at https://www.otsuka.co.jp/en/company/globalnews/detail.php?id=240&date=2017-04-22 On April 22, 2017, the Polycystic Kidney Disease (PKD) Foundation honored Otsuka Pharmaceutical for our long-standing and successful commitment to develop an innovative, first-in-class drug treatment for autosomal dominant polycystic kidney disease (ADPKD) and for its collaboration with the foundation.  “Working together with basic science funded by PKD Foundation and the research and development capabilities of Otsuka, tolvaptan has become the first drug approved in Japan, Canada and the European Union, hopefully this landmark drug will soon become available in the United States as well for the treatment of ADPKD. The Foundation applauds the unwavering commitment of Otsuka to bring this important new therapy to the marketplace. It is for this persistence and recognition of the unmet medical need of PKD patients in the US and worldwide that the PKD Foundation has honored Otsuka at its Gratitude dinner in San Francisco this spring”, said Andy Betts, the chief executive of the PKD Foundation.  Yoshitaka Yamamura, a researcher at Otsuka’s Tokushima Research Institute who pursued research on the antidiuretic hormone vasopressin for decades, and Frank Czerwiec, vice president of Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization, Inc., who was deeply influential in initiating and steering the global development of tolvaptan for ADPKD, accepted the award on behalf of the company. For over 20 years, Otsuka has pursued developing a treatment for ADPKD – a condition that causes cysts to proliferate in the kidneys and often results in end stage kidney disease, requiring dialysis or kidney transplantation. During this period, the PKD Foundation has worked side-by-side with us as advocates for disease state awareness. In addition, they have been instrumental in recruitment of participants in clinical trials and helping advance the compound through the regulatory process. “Otsuka's purpose starts with addressing patient problems,” said Dr. Czerwiec. “In the case of ADPKD, we have built upon research initiated by highly motivated researchers inside and outside the company. In this sense, ours is a symbiotic relationship where we each achieve our goal faster through collaborative research.” Mr. Yamamura and Dr. Czerwiec, on behalf of the company, are humbled to see Otsuka honored at this year’s Gratitude Benefit. “To share in recognition that is given to physicians and patients who fight this disease is a great honor,” Dr. Czerwiec said.

Read the original article with photos at: https://www.otsuka.co.jp/en/company/globalnews/detail.php?id=227&date=2016-04-20 The Minister of Education, Culture, Sports, Science and Technology awarded Otsuka Pharmaceutical Co., Ltd. two commendations for Science and Technology in Tokyo, Japan. One of the prizes for Science and Technology, in the Development Category, was for the research and development of delamanid. It is an effective treatment for multi-drug resistant tuberculosis. The other prize was for the development of tolvaptan, an antagonist of the vasopressin V2 receptor. The commendations were presented in late spring in a ceremony held in the Ministry of Education, Culture, Sports, Science, and Technology. Each year, 9.6 million people are newly infected by tuberculosis (TB). Of these cases, 480,000 patients develop multidrug-resistant tuberculosis (MDR-TB). And in that group, 22% develop extensively drug-resistant tuberculosis (XDR-TB). There have been no new anti-TB drugs developed since the introduction of rifampicin over forty years ago. Senior director of the Pharmaceutical Business Division, Mr. Makoto Matsumoto, Ph.D., said, “Delamanid was approved as a new drug for the first time in approximately 40 years. However, many besides those being awarded this time contributed their efforts and cooperation during the approval process, which took over 20 years.” He continued to thank, “all those who were involved from the discovery and development of delamanid to the approval of the drug. Otsuka will continue its efforts to increase the number of patients using the drug, and will continue contributing to tuberculosis treatment worldwide.” Delamanid was approved in Japan, Europe, and Korea in 2014. The commendation was awarded to delamanid for its contribution to the medical care of TB, by addressing the pressing need for new effective treatments to the increasing occurrence of MDR-TB. A doctor looking for a drug that helped his patients excrete only water unlike other diuretics inspired Otsuka Pharmaceutical to start researching for an agent to do just that. It was discovered that this vasopressin V2 receptor antagonist may hinder the proliferation and enlargement of the cysts in the hereditary disease Autosomal Dominant Polycystic Kidney Disease (ADPKD). Otsuka subsequently played a pivotal role in the clinical development of tolvaptan for ADPKD, and it is presently the only treatment option known to delay the long-term progression of ADPKD. “I heard that this award commemorates ‘people’ who make achievements, and I am deeply moved by the fact that my life’s work involving the discovery and development of tolvaptan, which I spent 30 years on, has been recognized,” said Mr. Yoshitaka Yamamura, senior director of the Pharmaceutical Business Division. “The ‘rugged’ drug discovery we started from scratch is now contributing to patients daily, and I am sincerely proud of that fact. I hope that new drug discoveries will be made for drugs that ‘originate in Tokushima and are the world’s first’.” The commendation was awarded to tolvaptan for its contribution to the medical fields of heart failure and liver cirrhosis, as an agent with a new mode of action of water diuresis, as well as the only treatment option known to delay the long-term progression of ADPKD.    

Read the full story with photos at: https://www.otsuka.co.jp/en/company/globalnews/2014/1204_01.html The 46th Annual Meeting of the Swiss Society of Nephrology (SSN) took place on December 4th and 5th in Interlaken, Switzerland. Over 300 nephrologists, researchers, and nurses, including all the Swiss KOLs attended the meeting which consisted of plenary sessions, oral communications, poster sessions and satellite symposia. New affiliate Otsuka Pharmaceutical (Switzerland) GmbH (OPCH) was present at the meeting with one of the first ADPKD disease awareness booths in Europe. The booth combined elements of the disease awareness campaign, market access, and PAG engagement. Also several leave pieces have been distributed and a survey on patient journey has been carried out with some of the physicians. Attendees of the congress were highly interested to learn more about Otsuka and its engagement in ADPKD. Especially in the lunch breaks the booth was well frequented. The exchange with many attendees has shown that the awareness of ADPKD among Swiss nephrologists is very high and the unmet medical need in this disease is largely recognized. The presence of OPCH with a disease awareness booth marks a successful milestone in the ADPKD awareness campaign. We were able to connect the unmet needs in ADPKD to the commitment of Otsuka, and position OPCH as the new player in the disease area of nephrology in Switzerland. We are looking forward to our presence at the 2015 Swiss Nephrology Congress.

Read the full story with photos at: https://www.otsuka.co.jp/en/company/globalnews/2014/0531_01.html   The Forum is a newly formed group of physicians and advocates in Europe dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD). The formation of the European ADPKD Forum (abbreviated as EAF) coincided with the 51st European Renal Association-European Dialysis and Transplant Association Congress that was held in Amsterdam, the Netherlands. The Forum is supported by Otsuka Pharmaceutical Europe Ltd. The original seeds of Otsuka’s engagement on ADPKD can be traced back to research done at Otsuka labs in Tokushima, Japan in the late 1980s on vasopressin, a hormone that increases water reabsorption in the kidneys. Otsuka shared the findings with university-based researchers around the world, and subsequent R&D has created significant scientific insights into ADPKD. The EAF initiative is co-chaired by Tess Harris, President of PKD International, and Dr. Richard Sanford, Consultant Clinical Geneticist at Addenbrooke’s Hospital, Cambridge, UK. Tess Harris (left), EAF co-chair and ADPKD patient commented: “ADPKD places a great emotional and physical strain on people with the condition and their families. ADPKD patients experience a diminished and sometimes impoverished quality of life and are at risk of dying prematurely. Healthcare professionals and the wider public simply aren’t as aware of ADPKD as they should be and this must be urgently addressed. The EAF initiative will do this by identifying areas for improvement in care inequalities and by establishing a framework in which expertise and learnings can be shared to tackle the ongoing concerns faced by the ADPKD patient and care-giving community throughout Europe.” The EAF is currently developing an expert report that will feature new evidence from the largest-ever survey of ADPKD patients. The report will draw attention to the emotional and physical burdens of living with the disease, as well as explore the potential barriers to the development of innovative treatments for ADPKD. “This EAF report will provide the most robust overview yet of the wide-ranging impact of ADPKD, how health services are currently set up to meet this challenge, and what changes are needed to improve care development and delivery,” says Dr Richard Sandford. The EAF report will be published in late 2014. The co-chairs and faculty of the EAF do not receive fees for their roles in the initiative and the opinions expressed in EAF publications are solely their own and are not necessarily shared by Otsuka. The EAF initiative aims to: •Increase awareness of the impacts of ADPKD on patients and health services •Recommend health policy strategies to improve ADPKD care, based on the latest scientific evidence and expert insight •Encourage and facilitate collaboration between the individuals and groups involved in the care and support of people with ADPKD. What is ADPKD? 　ADPKD is a disease arising from one of two possible genetic mutations in which innumerable cysts (sacs in which fluid accumulates) form in the kidney, leading to gradual diminution of renal function. In most cases symptoms begin to show up in the third or fourth decade of life in the form of complaints such as blood in the urine, abdominal or low back pain, and abdominal distention. Also, hypertension may occur before the damage done to the kidneys by ADPKD becomes apparent. 　Approximately. 50% of ADPKD patients experience end-stage renal disease by age 59 and 75% reach ESRD by age 70. The disease occurs relatively frequently among genetic disorders and approximately 200,000 people have been diagnosed with ADPKD in Europe, 120,000 in the U.S. and 30,000 in Japan.

Polycystic kidney disease is an inherited disorder where clusters of cysts develop within the kidneys, causing the kidneys to enlarge and lose function over time. The cysts, which are noncancerous sacs containing fluid, vary in size, and they can grow to be large. This disorder can occur in children and adults.The two main types of polycystic kidney disease, caused by different genetic flaws, are: Autosomal dominant polycystic kidney disease (ADPKD). Signs and symptoms of ADPKD often develop between the ages of 30 and 40. In the past, this type was called adult polycystic kidney disease, but children can develop the disorder.Only one parent needs to have the disease for it to pass to the children. If one parent has ADPKD, each child has a 50% chance of getting the disease. This form accounts for most of the cases of polycystic kidney disease.  Autosomal recessive polycystic kidney disease (ARPKD). This type is far less common than is ADPKD. The signs and symptoms often appear shortly after birth. Sometimes, symptoms don't appear until later in childhood or during adolescence.Both parents must have abnormal genes to pass on this form of the disease. If both parents carry a gene for this disorder, each child has a 25% chance of getting the disease. Polycystic kidney disease also can cause cysts to develop in the liver and elsewhere in the body. The disease can cause serious complications, including high blood pressure and kidney failure.The disease varies greatly in its severity, and some complications from polycystic kidney disease are preventable. Lifestyle changes and treatments might help reduce damage to the kidneys from complications, but long-term interventions, including dialysis or kidney transplant, are sometimes needed.On this special Ask the Mayo Mom edition of the Mayo Clinic Q&A podcast, host Dr. Angela Mattke is joined by Dr. Christian Hanna, a pediatric nephrologist with Mayo Clinic Children's Center to discuss PKD in children. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy